Back to today’s briefing

Story perspectives

Breakthrough Therapy Shrinks Tumors, Sparks Immune Response

3/18/2026

37 8 Full Breakdown

Summary

Story summary

In a phase 1 trial at Rockefeller University, 2141-V11 produced tumor shrinkage in six of 12 patients and complete remission in two.
The therapy was injected directly into tumors, reducing severe side effects typically seen with CD40 therapies.
Immune responses were observed in non-injected tumors.
Ongoing larger trials aim to explain response variation and identify predictors of success.
The findings were published in Cancer Cell.

1 of 1

Story summary

In a phase 1 trial at Rockefeller University, 2141-V11 produced tumor shrinkage in six of 12 patients and complete remission in two.
The therapy was injected directly into tumors, reducing severe side effects typically seen with CD40 therapies.
Immune responses were observed in non-injected tumors.
Ongoing larger trials aim to explain response variation and identify predictors of success.
The findings were published in Cancer Cell.